PL EN
PRACA POGLĄDOWA
Mucormycosis and COVID-19
 
Więcej
Ukryj
1
Department of Experimental Embryology, Institute of Genetics and Animal Biotechnology of the Polish Academy of Science, Polska
2
Cell Cycle Group, Faculty of Medicine,, Univ Rennes, UMR 6290, CNRS, Institute of Genetics and Development of Rennes (IGDR), France
AUTOR DO KORESPONDENCJI
Jacek Zbigniew Kubiak   

Jacek Z. Kubiak UMR 6290, CNRS/UR1, IGDR, Faculty of Medicine; 2 Ave. du Prof. Leon Bernard, 35043 Rennes cedex, France email: jacek.kubiak@univ-rennes1.fr
Data nadesłania: 12-10-2021
Data akceptacji: 17-01-2022
Data publikacji: 07-03-2022
 
LW 2022;100(1):25–27
 
SŁOWA KLUCZOWE
DZIEDZINY
inne
 
STRESZCZENIE
This article presents the current situation regarding the spread of mucormycosis. Since mucormycosis is a very poorly known disease in Poland, we present here only the most important facts and observations regarding the relationship of this mycosis with COVID-19. We are dealing with a wave of infections, mainly in India, caused by the so-called black fungus. The increase in the number of infections and their spread also outside of India is directly related to the COVID-19 pandemic, and more specifically to the use of drugs containing corticosteroids or anti-interleukins, such as tocilizumab, which suppress the patients’ immune system. There are voices of specialists warning against underestimating mucormycosis and related mycoses, such as aspergillosis, and calling for more research on these diseases to find effective treatments and eventual preventive measures.
eISSN:1509-5754
ISSN:0024-0745